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Abstract
Background: Triple-drug regimens are the gold standard for HIV therapy. Nucleos(t)ide reverse transcriptase
inhibitors (NRTIs) reducing regimens are used to decrease drugs toxicity, exposure and costs. Aim of our study was
to evaluate trends of biochemical and inflammatory indices in patients switching to dual therapy (DT).
Methods: We included patients that a) switched to a DT from 2007 to 2015 from a tenofovir/abacavir-based triple
regimen b) previously maintained a triple and c) subsequently a dual regimen for 12 months with virological
suppression. We retrieved data measured at 5 points (at the switch, 6 and 12 months before and after switch). We
used platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR) and CD4/CD8 ratio as inflammatory
indices. We assessed temporal trends of viro-immunological, biochemical and inflammatory parameters.
Results: Overall, 364 and 65 patients switched from a tenofovir- and an abacavir-triple regimen, respectively.
In the tenofovir-reducing group, creatinine clearance and lipids raised after the switch. There was a significant
increase in both CD4+ cells and CD4/CD8. CD8+ cells rose after the switch, while opposite trend was found for PLR.
In the abacavir-reducing group total lipids showed a decrease during the first 6 months after the switch and then
stabilized. An increase of CD4+ and a decrease of CD8+ cells was observed during the study period, although not
statistically significant. While CD4/CD8 remained stable after simplification, PLR decreased significantly after
6 months, then returning to baseline.
CD8+ cells increased in the tenofovir-reducing group despite a viro-immunological response. Intriguingly, PLR
decreased, maintaining this trend for 12 and 6 months after tenofovir and abacavir interruption respectively.
Conclusions: Increased PLR has been linked to hypercholesterolemia and metabolic-syndrome, while high CD8+
cells count to increased risk of non-AIDS-related events regardless of CD4 T-cell recovery and to virological failure.
Whether these findings may have clinical implications, and which role DT plays on the immune system and on
inflammation should be further investigated.
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Background
Since the start of the epidemic in the early eighties, huge
efforts have been made in order to develop effective ther-
apies against HIV virus [1]. Triple-drug regimens have
proved their efficacy in controlling viral replication [2] and
are now considered the gold standard for the treatment of
HIV infection both in antiretroviral-naïve and in
antiretroviral-experienced patients. These regimens nor-
mally include two nucleos(t)ide reverse transcriptase inhib-
itors (NRTIs) as a backbone, plus one core agent drug
from another class: protease inhibitors (PIs), integrase in-
hibitors (INSTIs) or nucleoside reverse transcriptase inhib-
itors (NNRTIs) [3–5]. Thanks to these therapies, patients
with HIV are now living longer, though experiencing a
higher prevalence of aging-related comorbidities, such as
metabolic disorders, renal, cardiovascular and liver diseases
in addition to neurocognitive impairment [6]. Whether
these events are due to adverse effects of long-term use of
combined antiretroviral therapy (cART) remains a matter
of concern [7]. Tenofovir disoproxil fumarate (TDF) and
abacavir (ABC), respectively co-formulated with emtricita-
bine and lamivudine, have been the two NRTIs combina-
tions most frequently used in clinical practice [5]. Both
these NRTIs are well tolerated, although adverse effects
often occur in patients who take them chronically. Indeed,
TDF has been associated with acute and chronic renal im-
pairment, small molecular weight proteinuria, nephrogenic
diabetes insipidus, nephrotic syndrome, Fanconi syndrome
[8, 9] and reduction in bone mineral density [10].
Moreover, yet still controversial [11, 12], ABC has
been associated with an increased cardiovascular risk
[13, 14]. Recently, NRTIs reducing regimens are used as
an alternative approach in clinical practice to decrease
drugs toxicities, exposure and costs in both cART-naïve
and experienced patients [15–17].
Due to the different pharmacokinetic characteristics of
each drug, triple drugs regimens offer more chances of an
adequate tissue penetrance and distribution, in order to
achieve a wider suppression of HIV replication [18]. The
efficacy of simplified regimens needs to be addressed by
further studies, and so the effects of reducing strategies on
systemic inflammation and immunoactivation.
Given that certain dual therapy regimens have already
proved to have good virological outcomes when com-
pared to standard triple therapy in cART-experienced
patient [19], aim of our study was to evaluate the trends
of simplification to dual therapy in a cohort of patients
coming from TDF or ABC-containing triple regimens,
focusing on biochemical and inflammatory changes.
Methods
The Italian MASTER cohort is a hospital-based multi-
center, open HIV cohort established in the mid-1990s,
with retrospective patients enrollment from 1986 to
1997 and prospective recruitment subsequently. Patients
are recruited from 8 HIV clinics in Italy. Inclusion cri-
teria include a positive HIV-1 or HIV-2 antibody test, or
a positive HIVRNA, and being in care in one of the par-
ticipating centers. As long as the cohort first objective
was to represent the epidemiological and clinical trend
of HIV infection through the country, enrollment in
MASTER is independent from the HIV disease stage,
degree of immunosuppression or use of antiretroviral
therapy. Clinical data are recorded for each patient in an
electronic database every three/four months and a data
check is performed at a central level every six months
[20]. In the present study, we included all patients that a)
switched to a dual therapy between January 2007 and June
2015 coming from a triple regimen that included
tenofovir/emtricitabine (TDF/FTC) or abacavir/lamivudine
(ABC/3TC) b) had been durably on a ABC/TDF-containing
triple therapy for 12 months before switching and c) have
maintained dual therapy for 12 months.
In the switch to dual therapy, those who were pre-
scribed regimen 1 to 3 (Table 1) suspended TDF and
ABC respectively co-formulated with emtricitabine and
lamivudine. In these patients the PI was maintained and
associated with 3TC. Those who were switched to regi-
men 4 suspended both the NRTIs, starting one INSTI
and maintaining the PI.
We retrieved data on gender, age, date of enrollment,
country of origin, HIV exposure risk and viral hepatitis
C co-infection from the MASTER electronic database at
the switchover date. The following parameters, mea-
sured at 5 different points of follow-up (12 months be-
fore, 6 months before, at the switch to dual therapy,
6 months after and 12 months after the switch), were
also collected: HIV-RNA, CD4 cell count, CD8 cell
count, neutrophils, lymphocytes and platelets counts,
total cholesterol, high density lipoprotein (HDL) choles-
terol, low density lipoprotein (LDL) cholesterol, triglyc-
erides, serum creatinine and transaminases.
The study was conducted in accordance with the
guidelines of the Declaration of Helsinki and the princi-
ples of Good Clinical Practice. The study protocol was
approved by the local ethics committees on the 4th of
August, 2009, reference number 708. Written informed
consent was obtained by all patients enrolled [20].
Outcomes
We evaluated temporal trends of virological and bio-
chemical parameters and inflammatory indices, before
and after the switch to dual therapy.
The creatinine clearance (CCr) was estimated from the
serum creatinine, weight and height according to the
Cockcroft Gault equation [21]. We used platelet-to-lym-
phocyte ratio (PLR), neutrophil-to-lymphocyte ratio
(NLR) and CD4/CD8 ratio as inflammatory indices.
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Statistical analysis
We performed a retrospective, multicenter, case
cross-over study [22]. The study period for each subject
went from 12 months before to 12 months after the
switchover date. The parameters were expressed in
means (standard deviations, SDs) or proportions as ap-
propriate, according to the follow-up points (12 months
before, 6 months before, at the switch to dual therapy,
6 months after and 12 months after the switch). We
compared the characteristics at the moment of switch-
over between subjects coming from tenofovir-based regi-
mens and those coming from abacavir-based regimens
using common statistical tests for comparison of means
(Student’s t-test) or proportions (Chi-squared test). We
assessed temporal trends of HIV-RNA, CD4 cell count,
CD8 cell count total, ALT, AST, cholesterol, HDL, LDL
triglycerides, CCr, lymphocytes, neutrophils, platelets,
PLR and NLR before and after the switch using mixed
models for repeated measures. In the analysis we per-
formed random effects mixed models in order to evalu-
ate the role of time (in months) on the changes in
biochemical parameters. These models had a random ef-
fect on subjects. Age, gender, previous AIDS event, HCV
and HBV co-infection are not potential confounders be-
cause they are fixed over time. A sensitivity analysis by
multiple imputation for missing data was performed.
This method requires that the data are missing at
random–not related to the missing values. If this
assumption holds, resulting estimates (i.e., regression
coefficients and standard errors) will be unbiased with
no loss of power. We also stratified the analysis accord-
ing to the regimens after switching (atazanavir, daruna-
vir, lopinavir-ritonavir and integrase inhibitor regimens).
The results of mixed models were expressed in terms of
coefficients and their 95% confidence intervals (CIs).
The coefficient should be interpreted as in a linear re-
gression model: an increase in one unit in time leads to
an increase in one unit in the outcome (biological pa-
rameters). We have used month as time unit.
All statistical tests were two-sided, where a level of sig-
nificance of 0.05 has been assumed. Statistical tests were
performed using Stata software version 12.0 (StataCorp,
College Station, TX, USA).
Results
A total of 6067 subjects were followed in the Master Cohort
between 2007 and 2015. TDF- and ABC- containing triple
regimens were prescribed at least once to 1702 and 745 pa-
tients, respectively. Overall, simplification rate to dual ther-
apy per 100 person-years was 8.83 (CI 95% 8.02–9.69) from
both TDF- and ABC-containing triple regimens, while it
was 7.50 (6.76–8.30) and 1.32 (1.02–1.68) for TDF- and
ABC-containing triple regimens, respectively.
A total of 429 subjects (70.2% males) with a mean age
of 49.8 years were included in this analysis. Demo-
graphic and clinical features are showed in Table 1.
Overall, 364 patients switched from a TDF-containing
triple regimen and 65 from an ABC-containing triple
regimen to a dual therapy.
Patients that discontinued TDF, compared to those sus-
pending ABC, had a lower prevalence of males (68.4% vs
80.0%), subjects with age ≥ 40 years (82.1% vs 92.3%) and ex-
perienced less virological failure (HIVRNA > 50 copies/ml)
(21.7% vs 38.5%) before the simplification.
Dual regimens prescribed were categorized as follows:
atazanavir/ritonavir (RTV) plus 3TC (regimen 1),
darunavir/RTV plus 3TC (regimen 2), lopinavir-RTV
plus 3TC (regimen 3), and raltegravir or dolutegravir
plus ritonavir boosted protease inhibitor (regimen 4).
Table 1 Demographic and clinical features at switch to
dual therapy
Variables From tenofovir/
emtricitabine
n (%)
(n = 364)
From abacavir/
lamivudine
n (%)
(n = 65)
p-valuea
Male 249 (68.4) 52 (80.0) 0.060
Age, in years, mean (SD) 48.1 (10.2) 51.0 (10.4)
< 40 65 (17.9) 5 (7.7) 0.093
40–49 145 (39.8) 26 (40.0)
≥ 50 154 (42.3) 34 (52.3)
Intravenous Drug Use 85 (27.6) 15 (25.9) 0.953
HCV co-infection 134 (36.8) 24 (36.9) 0.987
CD4 cell count, cell/mm3,
mean (SD)
631.6 (295.6) 678.1 (342.2)
< 200 15 (4.9) 1 (1.8) 0.674
200–349 35 (11.4) 8 (14.6)
350–499 51 (16.7) 8 (14.6)
≥ 500 205 (67.0) 38 (69.1)
Positive HIV-RNA, > 37
copies/mL
37 (12.3) 6 (11.3) 0.835
Time (months) in
tenofovir/abacavir
110.0 (68.3) 110.4 (78.7) 0.970
Dual regimens:
Atazanavir/r + 3TC
(regimen 1)
121 (33.2) 17 (26.2) < 0.001
Darunavir/r + 3TC
(regimen 2)
84 (23.1) 14 (21.5)
Lopinavir/r + 3TC
(regimen 3)
31 (8.5) 1 (1.5)
Raltegravir/dolutegravir+
PI/r (regimen 4)
128 (35.2) 33 (50.8)
Number of patients with
at least one previous
virological failure
79 (21.7) 25 (38.5) 0.004
aWe used Student t-test for comparison of means Chi-squared test for
comparition of proportions
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In the TDF reducing-group, when compared to the
ABC reducing-group, there was a higher proportion of
subjects that underwent regimen 1 (33.2% vs 26.2%) and
regimen 3 (8.5% vs 1.5%), and a lower proportion of sub-
jects in regimen 4 (35.2% vs 50.8%). The proportions of
subjects in regimen 2 were similar in the two groups.
Biological parameters before and after switch in the
TDF-reducing therapy group. Table 2
The CCr significantly decreased from 92.1 to 88.6 ml/min
before the switch, and rose from 88.6 to 95.8 ml/min after
the switch (p < 0.001 for both comparisons). CCr showed a
significant biphasic trend with a decrease before the switch
and an increase after the switch in all the regimens exclud-
ing regimen 1, where CCr was stable around 95 ml/min
(p = 0.132). The best CCr recovery was observed after
switching to the INSTI plus PI regimen (regimen 4)
(p < 0.001) (Fig. 1).
With regard to the lipid pattern, total, HDL and LDL
cholesterol and triglycerides showed a fluctuation over
time with an overall increase mainly during the first
6 months after the switchover to a dual therapy. After
switching to dual therapy, the total cholesterol rose
significantly in subjects undergoing regimens 1, 2 and 4
(p < 0.005 for all comparisons). HDL increased in
regimen 1 (p < 0.001), whereas LDL rose significantly in
regimens 2 and 4 (p < 0.001 for both). Triglycerides de-
clined in the year before the switch in regimen 2 from
151.3 to 135.2 mg/ml (p = 0.045) and increased after the
switch in regimen 4 from 176.7 to 218.2 mg/ml (p = 0.022)
(Fig. 2).
There was a significant increase in both CD4+ cell
count and CD4/CD8 over the study period. On the con-
trary, the CD8+ cell count rose only after the switch from
872.3 to 919.2 cell mm3 (p = 0.007). When analyzing the
different dual regimens, CD8+ cells trend showed a sig-
nificant increase only for regimen 4 (p = 0.049) after the
switch (Fig. 3).
Concerning CD4/CD8 ratio (Fig. 4), we observed a
persistent rise before and after simplification only for
regimens 1 and 2 (p < 0.001 for both).
We did not observe any variations of the NLR during
the study period. PLR remained stable before and de-
creased after the switch to dual therapy (from 118.7 to
105.0, p < 0.001). When the 4 regimens were analyzed
separately, there was a significant reduction of PLR after
the switch for regimen 1 (from 133.4 to 116.7, p < 0.001),
regimen 2 (117.3 to 103.4, p = 0.007) and regimen 4
(from 105.4 to 91.4, p = 0.038) (Fig. 4).
Biological parameters before and after switch in the
ABC-reducing group. Table 3
Total and LDL cholesterol and triglycerides showed a
decrease during the first 6 months after the switch and
then stabilized. Anyway, only the changes on total chol-
esterol were statistically significant. Overall there was an
increase of the CD4+ cells and a decrease of CD8+ cells
during the study period, although not statistically signifi-
cant. Moreover, CD4/CD8 remained stable after simplifi-
cation. There were no significant changes of NLR and
PLR over the observational period. Intriguingly, PLR de-
creased significantly after 6 months from simplification
(coeff. -2.07 95% CI -3.43, − 0.71; p = 0.003), returning
then to baseline levels. Due to the low number of sub-
jects in this group, we didn’t perform a stratified analysis
for each regimen.
Discussion
An improvement in renal function and a worsening in the
lipids profile were observed when TDF was removed from
triple regimens, while ABC suspension was followed by a
significant decrease in total cholesterol only. With regard
to the immune reconstitution and to the inflammatory
status, CD4+ cell counts and CD4/CD8 raised after
simplification, especially in the TDF-reducing group.
Intriguingly, CD8+ cells also increased, but only in the
TDF-reducing group.
PLR, but not NLR level, decreased after NRTIs reduc-
tion. This trend was maintained for 12 months after
TDF interruption and for only 6 months after the sus-
pension of ABC.
During the study period, an overall simplification rate
to dual therapy of 8.83/100 person-years has been ob-
served. Simplification rate was higher from TDF- than
from ABC-containing triple regimens (7.50/100 vs 1.32/
100 person-year). Despite TDF-containing triple regi-
mens were the preferred choice for most patients, physi-
cians had suspended TDF more than ABC, as previously
described in other studies focused on dual therapies
[16]. This could reflect somehow the tendency to switch
to a TDF-free dual-therapy regimen because of kidney
or bone adverse effects, especially in an aging popula-
tion. In the near future, this trend could be reverted
thanks to the introduction of tenofovir alafenamide
(TAF), which is thought to be safer in terms of renal and
bone toxic effects [23].
Nowadays, the strategy of reducing the number of drugs
in the cART regimen in order to reduce, or prevent,
NRTIs-related toxicities and drug-to-drug interactions is
not uncommon. Anyway, very few dual regimens are rec-
ommended by national and international guidelines [3–5].
Recently, in an Italian geriatrics cohort, it has been
pointed out that around 25% of patients received uncon-
ventional dual regimens (mainly NRTIs-sparing), reaching
an overall viral suppression in about 95% of patients [24].
NRTIs-sparing dual therapies were also the most frequent
regimen used in our study (protease inhibitor plus inte-
grase inhibitor). Although this regimen is not mentioned
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in the guidelines, enough information, from both trials
[15, 16] and observational studies [25], have proved their
efficacy and safety profile.
As previously observed in other studies [26–28], an
improvement of kidney function and a disappearance of
the lipid-lowering effect of TDF were shown after TDF
discontinuation, while on the other hand, we observed
an improvement of lipids profile after ABC suspension.
To the best of our knowledge, no previous studies, apart
from Di Giambenedetto and Fabbiani et al. [29, 30], spe-
cifically focused on the changes in renal function and
lipids concentration during the switch from a triple to a
dual cART regimen. Anyway, none of these two studies
analyzed results from a TDF- or an ABC-stopping therapy
separately. In the cohort from Di Giambenedetto, 82% of
patients interrupted TDF, and the modifications observed
in lipids and in the renal function were similar to ours.
Information on the impact of the various cART regi-
mens on inflammation/immunoactivation remain very
limited [31–35]. Actually, there is no consistent evidence
about any differences in the reduction of inflammation
and immune activation between protease and integrase
inhibitors [33, 36, 37]. TAF and TDF (when included in
a triple regimen) seem to have an equivalent impact on
monocyte activation and on the reduction of systemic
inflammation [38]. Moreover, no studies focused on the
effects that NRTIs-reducing strategies may have on
inflammatory markers in an overall virologically sup-
pressed cART-experienced population.
Here we show that CD8+ cells increased in the group
of patients stopping TDF, but not in those stopping
ABC. The meaning of this trend in patients switching to
a TDF-reducing therapy needs further studies and a lon-
ger follow-up in order to discover whether this finding
could have clinical and/or virological implications.
Fig. 1 Temporal trends of glomerular filtration rate (CCr) before and
after switch in the TDF-reducing therapy group
Fig. 2 Temporal trends of lipids before and after switch in the TDF-reducing therapy group
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Persistent inflammation is a predictor for clinical
events and mortality in HIV-infected patients. Anyway,
no agreement has been achieved about which one
should be the best marker of inflammation in these cases
[39, 40]. Persistently elevated CD8+ cells counts during
long-term cART have been linked with increased risk of
non-AIDS-related events in HIV-infected patients, re-
gardless of CD4 T-cells recovery, and have been related
with a chronic inflammation status, and with increased
immuneactivation markers such as IL-6, soluble CD14
and d-dimer [39, 41, 42]. Higher CD8+ cells counts at
cART initiation, or an increase in CD8+ cell count dur-
ing cART, seem to be predictive of virological treatment
failure [43–45]. In a study from Mussini et al. [46], a
lower increase in CD4/CD8 ratio due to a raise in CD8+
cells was found in those switching to a mono/dual-therapy,
when compared to those remaining on a standard triple
regimen. Anyway, mono and dual therapies were not sepa-
rated in this analysis, and the comparative group was com-
posed by patients who remained on a triple regimen.
The persistence of HIV replication in sanctuary sites,
despite undetectable viremia in plasma, could explain
the persistence of systemic inflammation and immune
activation, especially because cART penetration into
viral reservoirs and sanctuary sites differs among differ-
ent antiretroviral drugs. NRTIs-reducing strategies could
alter the intracellular total cART concentrations when
compared to plasma concentrations [20, 47, 48]. Very
few data are available about what happens in HIV sanc-
tuaries and reservoirs when simplified cART regimens
are used in persistently HIV suppressed patients. ATLAS
study showed that a simplification strategy had the same
impact on the cellular viral reservoir when compared to
triple regimen, but no data are available about
immuno-inflammatory trends [49].
Recently, two biomarkers derived from common blood
parameters, the neutrophil to lymphocyte ratio (NLR)
and the platelet to lymphocyte ratio (PLR), have shown
to be indicative of systemic inflammation [50, 51]. In
previous studies from the MASTER cohort, we explored
the role of NLR and PLR scores as predictors of cardio-
vascular events, prognosis of cancer and all-cause mor-
tality, proving that they can have a role as positive
predictors of these events [52–56].
In the present study, NLR and PLR levels were low
throughout the follow-up period. Anyway, we observed
a further significant decrease of PLR, but not of NLR
Fig. 3 Temporal trends of CD8+ cells before and after switch in the
TDF-reducing therapy group
Fig. 4 Temporal trends of CD4/CD8 ratio and platelet/lymphocyte ratio (PLR) before and after switch in the TDF-reducing therapy group
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levels, after NRTIs interruption. This trend was main-
tained for 12 months after TDF interruption, and for only
6 months after the discontinuation of ABC. More studies
are needed to explore whether these fluctuations may have
a clinical significance, or they are a casual feature. Data
coming from either HIV-infected and -uninfected persons
could explain this variation.
Previously, poor renal function [57] and low levels of
vitamin D [58] have been associated with systemic in-
flammation during HIV infection. In HIV-uninfected
people PLR was found to be an independent predictor of
25(OH)D levels along with PTH, calcium, sex and cre-
atinine [59]. In our study, Vitamin D values were not
available. Nevertheless, the impact of TDF on bone me-
tabolism and loss of bone mass is known [60]. Whether
the decrease of PLR is related with an improvement on
the bone turnover and/or of the bone mass as a conse-
quence of TDF interruption, must be deepened.
PLR was also found to be superior to NLR in predict-
ing higher inflammation in end-stage renal disease in
HIV-negative patients [61].
The PLR variation following ABC-reducing therapy
could be mediated by the lipid profile improvement.
Hypercholesterolemia has been linked to systemic and
vascular inflammation through several cytokines [62, 63].
Increased PLR has been significantly associated with both
presence and severity of metabolic syndrome in HIV-un-
infected people [64]. Here, we observed a reduction on
total cholesterol during the first 6 months after ABC sus-
pension (maintained also after 12 months) and a concomi-
tant significant decrease of PLR after 6 months, but not
after 12 months from ABC suspension. More studies are
needed in order to correlate the variations in the lipid
profile with this simple and cheap indirect indicator
of inflammation.
Obviously, several limitations are present in our study.
They include the weakness of a retrospective study. Sec-
ond, the sample size in the ABC-stopping group and in
the several subgroups of dual therapies were relatively
small and the results need to be confirmed in larger
populations of patients. A further limitation is that asso-
ciations between PLR and other inflammatory bio-
markers were not measured and possible confounders of
inflammation were not assessed.
This was not a prospective controlled study, so we
cannot draw cause-and-effect relationships from our
findings about inflammation. Despite the difficulties in
using retrospective study results, strength of our study is
the large sample size of a multicenter cohort.
Conclusions
To conclude, in our study we confirm the disappearance
of the lipid-lowering effect and the positive impact on
creatinine clearance in those discontinuing TDF, and we
observed a decrease of total cholesterol after ABC sus-
pension. Moreover, we found an increase in the CD8+
T-cells besides a PLR reduction in those patients who
discontinued TDF and switched to a dual therapy.
Larger controlled studies are required to confirm our
findings and to better elucidate the relationship between
stopping NRTIs and PLR or- CD8 cells fluctuations.
Moreover, a longer follow-up could elucidate whether
these findings could correlate with specific clinical events.
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